PATENT CLAIM ANALYSIS

Application Number: 15746001
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "252120"]

Abstract:
Provided in the present invention are a compound PAC-1 in amorphous form, an oral pharmaceutical composition comprising the compound PAC-1 in amorphous form, and a use of the compound PAC-1 in amorphous form in the preparation of the oral pharmaceutical composition. The PAC-1 in amorphous form displays an obviously lower neurotoxicity than PAC-1 in crystal form, and is more suitable for being used to develop drugs for treating diseases such as tumours, especially metastatic tumours and the like.

Claim (Index 13):
The oral pharmaceutical composition according to  claim 2  further comprising a crystal form of PAC-1 or a salt thereof, wherein the amorphous form of PAC-1 is present in an amount of 80% or more by weight with respect to the total amount of the PAC-1 or a salt thereof in crystal form and the PAC-1 in amorphous form.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 1.82609
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14382546', '15243860', '14383460', '13379497', '14263886']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7142288533687012
- 35 USC 102 Novelty (BERT): 0.5169110278460837
- Combined Prediction Score: 0.6944970708164395
- Mean Citation Score: 220.49763
- Max Citation Score: 227.74901
- Similarity Product: 131.5895579363072

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test